Wrap Text
Investor Webinar for Noble Africa
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
INVESTOR WEBINAR FOR NOBLE AFRICA
Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company
Noble Africa was created to unlock the value of Renergen's Virginia Gas Project
through a public company focused on helium and LNG
Learn why the Virginia Gas Project is positioned to become one of the world's most
strategic helium developments as global supply tightens and demand accelerates
DALLAS and ANN ARBOR, Mich., July 17, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc.
(NASDAQ: ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on
developing technologies and processes for the production of critical materials used in
multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or "NDRA"),
a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of
steatotic liver disease (SLD), today announced that RedChip Companies will host an
investor webinar featuring Noble Africa, a wholly owned subsidiary of ASP Isotopes and the
holding company for Renergen Limited, on Tuesday, July 21, 2026, at 4:15 p.m. ET. The
webinar will highlight Noble Africa's proposed merger (the "Proposed Merger" and, together
with the related transactions, the "Proposed Transactions") with ENDRA, which, if
completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company
trading under the ticker symbol "NOBA." The discussion will focus on Renergen's Virginia Gas
Project and Noble Africa's strategy to become a publicly traded helium platform.
The webinar will feature Paul Mann, Chief Executive Officer of ASP Isotopes and Renergen,
who will serve as Chief Executive Officer of Noble Africa following completion of the
Proposed Transactions. Mr. Mann will discuss Renergen's Virginia Gas Project, one of the
world's highest-grade commercial helium resources and one of the few new large-scale
helium developments positioned to enter production as global supply tightens. The project
combines the production of helium—an irreplaceable material used in semiconductors, MRI
systems, aerospace and other critical technologies—with liquefied natural gas (LNG),
expected to create a differentiated dual-revenue platform.
Mr. Mann will outline the roadmap for the Virginia Gas Project, including the anticipated ramp
to Phase 1 nameplate production in 2026, the significant expansion planned under Phase 2,
key operational and financing milestones, and how the proposed Nasdaq listing is expected
to position the combined company to execute its long-term growth strategy.
A live Q&A session will follow the presentation.
To register for the free webinar, please visit:
https://www.redchip.com/webinar/NDRA/81441255630
Questions can be pre-submitted to NDRA@redchip.com or online during the live event.
About ASP Isotopes Inc.
ASP Isotopes is developing a differentiated isotope enrichment platform to strengthen global
supply chain access to critical materials used in nuclear medicine, next-generation
semiconductors, and nuclear energy. ASP Isotopes' proprietary technologies, the
Aerodynamic Separation Process ("ASP technology") and Quantum Enrichment ("QE
technology"), are designed to enable the production of isotopes for a range of industrial and
advanced technology applications. ASP Isotopes operates isotope enrichment facilities in
Pretoria, South Africa, focused on the enrichment of low atomic mass elements, or light
isotopes. For more information, please visit www.aspisotopes.com.
About Renergen Limited
Renergen Limited, a subsidiary of ASP Isotopes Inc., is a company incorporated under the
laws of the Republic of South Africa whose principal asset is its 94.5% equity ownership in
Tetra4 Proprietary Limited. Tetra4 Proprietary Limited holds an onshore petroleum
production right and engages in the production and liquefaction of natural gas and the
exploration and development of helium resources at the Virginia Gas Plant located in Free
State Province, South Africa.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ®), a
ground-breaking technology being developed to assess tissue fat content and monitor tissue
ablation during minimally invasive procedures, at the point of patient care. TAEUS ® is
focused on the measurement of fat in the liver as a means to assess and monitor steatotic
liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions
that affect over two billion people globally, and for which there are no practical diagnostic
tools.
Important Additional Information and Where to Find It
This communication relates to the Proposed Transactions involving ENDRA, ASP Isotopes,
Renergen and Noble Africa and may be deemed to be solicitation material in respect of the
Proposed Transactions.
In connection with the Proposed Transactions, ENDRA intends to file relevant materials with
the U.S. Securities and Exchange Commission (the "SEC"), including a registration
statement on Form S-4 (the "Form S-4") that will contain a proxy statement (the "Proxy
Statement") and prospectus. This communication is not a substitute for the Form S-4, the
Proxy Statement or for any other document that ENDRA may file with the SEC and/or send to
its stockholders in connection with the Proposed Transactions. INVESTORS AND
STOCKHOLDERS OF ENDRA ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT
AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS
ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR
ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT ENDRA, ASP ISOTOPES, RENERGEN, NOBLE AFRICA,
THE PROPOSED TRANSACTIONS AND RELATED MATTERS.
Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy
Statement and other documents filed by ENDRA and ASP Isotopes with the SEC (when they
become available) through the website maintained by the SEC at www.sec.gov. ENDRA'S
Internet website address is www.endrainc.com. ENDRA's Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and
amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the
Exchange Act are available free of charge through the investor relations page of its Internet
website as soon as reasonably practicable after it electronically files such material with, or
furnishes such material to, the SEC.
Participants in the Solicitation
ENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors and managers
and certain of their executive officers and other members of management may be deemed
to be participants in the solicitation of proxies from ENDRA's stockholders in connection
with the Proposed Transactions under the rules of the SEC. Information about ENDRA's
directors and executive officers, including a description of their interests in ENDRA, is
included in ENDRA's most recent Annual Report on Form 10-K for the year ended December
31, 2025. Information about ASP Isotopes' directors and executive officers, including a
description of their interests in ASP Isotopes, is included in ASP Isotopes' most recent
Annual Report on Form 10-K for the year ended December 31, 2025. Additional information
regarding the persons who may be deemed participants in the proxy solicitations, including
the directors and executive officers of Renergen, and a description of their direct and indirect
interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy
Statement and other relevant materials to be filed with the SEC when they become available.
These documents can be obtained free of charge from the sources indicated above.
No Offer or Solicitation
This press release is not intended to and does not constitute a solicitation of a proxy, consent
or approval with respect to any securities or in respect of the Proposed Transactions or an
offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase
or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall
there be any sale, issuance or transfer of securities in any jurisdiction in contravention of
applicable law.
No offering of securities shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in
accordance with applicable law, or an exemption therefrom. Subject to certain exceptions
to be approved by the relevant regulators or certain facts to be ascertained, the public offer
will not be made directly or indirectly, in or into any jurisdiction where to do so would
constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means
or instrumentality (including without limitation, facsimile transmission, telephone and the
internet) of interstate or foreign commerce, or any facility of a national securities exchange,
of any such jurisdiction.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they
are based only on our current beliefs, expectations, and assumptions regarding the future of
our business, future plans and strategies, projections, anticipated events and trends, the
economy, and other future conditions. Forward-looking statements can be identified by
words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may,"
"might," "plans," "projects," "will," and words of a similar nature.
Examples of forward-looking statements include, but are not limited to, statements relating
to the Proposed Transactions; the expected structure, timing and the completion of the
Proposed Merger, the Proposed Transactions and the expected effects, perceived benefits
or opportunities of the Proposed Transactions; the combined company's listing on Nasdaq
after the closing of the Proposed Transactions; expectations regarding the structure, timing
and completion of the Proposed Transactions, including investment amounts from
investors, timing of closing of the Proposed Transactions, expected proceeds, expectations
regarding the use of proceeds, and impact on ownership structure; the anticipated timing of
the closing of the Proposed Transaction; the expected executive officers and directors of the
combined company; each company's and the combined company's expected cash position
at the closing of the Proposed Transactions and cash runway of the combined company
following the Proposed Transactions; the future operations and pipeline, estimates of
financial position, competitive landscape, addressable market and strategic and financial
initiatives of the combined company; the nature, strategy and focus of the combined
company; statements regarding the continuation of Renergen's Virginia Gas Project and its
funding timeline and other statements that are not historical fact.
Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that are difficult to predict, many of
which are outside our control. Actual results, financial condition, and events may differ
materially from those indicated in the forward-looking statements based upon a number of
factors. Forward-looking statements are not a guarantee of future performance or
developments. You are strongly cautioned that reliance on any forward-looking statements
involves known and unknown risks and uncertainties. Therefore, you should not rely on any
of these forward-looking statements.
There are many important factors that could cause actual results and financial condition to
differ materially from those indicated in the forward-looking statements, including, but not
limited to: the outcomes of various strategies and projects undertaken by Renergen; the
potential impact of laws or government regulations or policies in South Africa or elsewhere;
Renergen's future capital requirements and sources and uses of cash; Renergen's ability to
obtain funding for its operations and future growth, including debt funding for Phase 2 of the
Virginia Gas Project; Renergen's reliance on the efforts of third parties; Renergen's ability to
complete Phase 1 and 2 of the Virginia Gas Project; the financial terms of any current and
future commercial arrangements; Renergen's ability to complete certain transactions and
realize anticipated benefits from acquisitions and contracts; Renergen's ability to comply
with the terms of the loan and credit facilities of Renergen's subsidiary Tetra4; the ability of
Renergen and its subsidiaries to retain and hire key personnel; the volatility of LNG and liquid
helium prices; Renergen's success in discovering, estimating and developing natural gas
and helium reserves; actions of competitors or regulators; limitations in the availability of,
and costs of, supplies, materials, contractors and services that may delay the drilling or
completion of wells or make such wells more expensive; the amount and timing of future
development costs; uncertainties inherent in estimating quantities of natural gas and helium
reserves and projecting future rates of production and timing of development activities; risks
relating to the lack of capital available on acceptable terms to finance the Renergen's
continued growth; the competitive nature of Renergen's industry; the risk that the conditions
to the closing or consummation of the Proposed Transactions are not satisfied, including the
failure to timely obtain approval of the Proposed Merger from ENDRA stockholders, if at all;
the risk that the proposed financings are not completed in a timely manner, if at all;
uncertainties as to the timing of the consummation of the Proposed Transactions and the
ability of each of ENDRA and Noble Africa to consummate the Proposed Transactions; risks
related to ENDRA's continued listing on Nasdaq until closing of the Proposed Transactions
and the combined company's ability to remain listed following the closing of the Proposed
Transactions; the ability to obtain debt financing on terms that are favorable, or at all; the risk
that Renergen does not receive funding from the U.S. DFC or Standard Bank SA or that such
funding is delayed; risks related to ENDRA's ability to correctly estimate its respective
operating expenses and its respective expenses associated with the Proposed Transactions,
as applicable, pending the closing of the Proposed Transactions, as well as uncertainties
regarding the impact any delay in the closing would have on the anticipated cash resources
of ENDRA, and other events and unanticipated spending and costs that could reduce
ENDRA's cash resources; risks related to the failure or delay in obtaining required approvals
from any governmental or quasi-governmental entity necessary to consummate the
Proposed Transactions; the occurrence of any event, change or other circumstance or
condition that could give rise to the termination of the merger agreement; the effect of the
announcement or pendency of the Proposed Merger on ENDRA's or Renergen's business
relationships, operating results and business generally; costs related to the Proposed
Merger; risks related to the market price of ENDRA's common stock relative to the value
suggested by the Proposed Merger; the outcome of any legal proceedings that may be
instituted against ENDRA, Noble Africa or any of their respective directors, managers, or
officers related to the Proposed Transactions; costs of the Proposed Transactions and
unexpected costs, charges or expenses resulting from the Proposed Transactions; changes
in regulatory requirements and government incentives; risks associated with the possible
failure to realize, or that it may take longer to realize than expected, certain anticipated
benefits of the Proposed Transactions, including with respect to future financial and
operating results, legislative, regulatory, political and economic developments, and those
uncertainties and factors; and the risk of involvement in litigation, including securities class
action litigation, that could divert the attention of the management of ENDRA or the
combined company, harm the combined company's business and may not be sufficient for
insurance coverage to cover all costs and damages, and the other risks and uncertainties
described in ENDRA's SEC reports, and under the heading "Risk Factors" in its most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, the factors disclosed in
Part I, Item 1A. "Risk Factors" of ASP Isotopes' Annual Report on Form 10-K for the fiscal year
ended December 31, 2025 (as amended) and in ASP Isotopes' subsequent reports filed with
the SEC, each of which are available at www.sec.gov, and in other filings that ENDRA and
ASP Isotopes have made and will make with the SEC in connection with the Proposed
Transactions, including the Form S-4 and Proxy Statement described above under
"Additional Information and Where to Find It".
Any forward-looking statement made by the parties in this press release is based only on
information currently available to the parties and speaks only as of the date on which it is
made. The parties undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future developments or otherwise. No
information in this press release should be interpreted as an indication of future success,
revenues, results of operations, or stock price. All forward-looking statements herein are
qualified by reference to the cautionary statements set forth herein and should not be relied
upon.
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447) NDRA@redchip.com
ASPI Contact
IR@ASPIsotopes.com
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.
17 July 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 17-07-2026 04:02:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
